Aridis Pharmaceuticals Stock Price, News & Analysis
Company Description
Aridis Pharmaceuticals (OTC Link: ARDS) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $8.9K.
ARDS stock has gained 100.0% over the past year. Shares last traded at $0.0002.
On a trailing twelve-month basis, Aridis Pharmaceuticals reported revenue of $3.1M with net income of -$30.4M. The company operates at a net profit margin of -982.6%.
This page provides a comprehensive overview of ARDS stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Aridis Pharmaceuticals (ARDS) stock last traded at $0.0002. Over the past 12 months, the stock has gained 100.0%. At a market capitalization of $8.9K, ARDS is classified as a micro-cap stock with approximately 44.6M shares outstanding.
Latest News
Aridis Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, clinical trial, fda approval. View all ARDS news →
SEC Filings
Aridis Pharmaceuticals has filed 2 recent SEC filings, including 2 Form SCHEDULE 13G/A. The most recent filing was submitted on May 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ARDS SEC filings →
Financial Highlights
Aridis Pharmaceuticals generated $3.1M in revenue over the trailing twelve months, operating income reached -$30.0M (-970.3% operating margin), and net income was -$30.4M, reflecting a -982.6% net profit margin. The company generated -$29.1M in operating cash flow. With a current ratio of 0.32, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Aridis Pharmaceuticals (ARDS) currently stands at 25.8 thousand shares, representing 0.1% of the float. Over the past 12 months, short interest has increased by 1460.8%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Aridis Pharmaceuticals (ARDS) currently stands at 1.7 days, down 28.5% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 73% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 7.4 days.
ARDS Company Profile & Sector Positioning
Aridis Pharmaceuticals (ARDS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ARDS often look at related companies in the same sector, including Syros Pharmaceut (SYRS), Navidea Biopharm (NAVB), Tracon Pharmaceu (TCON), PaxMedica, Inc. (PXMD), and Endonovo Therape (ENDV). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ARDS's relative position within its industry.